Nasal polyps are the common end-point of a number of conditions characterised by inflammation and are rarely ‘curable’ in its true sense. After consideration of the underlying aetiology and confirmation of the diagnosis, they are normally managed by a combination of medical and surgical interventions. Of these, topical corticosteroids have proved to be the medical treatment of choice.
The objectives of the medical management are to eliminate or reduce the size of polyps, re-establish nasal airway and nasal breathing, improve or restore the sense of smell, and prevent recurrence of nasal polyps. The mechanism of action of corticosteroids may be by a multifactorial effect on various aspects of the inflammatory reaction, the effect being initiated by their binding to a specific cytoplasmic glucocorticoid receptor. At a cellular level, there is a reduction in the number of antigen-presenting cells, in the number and activation of T cells, in the number of mast cells, and in the number and activation of eosinophils.
When polyps are large (grade 3) topical medication is difficult to instil in a very blocked nose and surgery or short term systemic corticosteroids may be required. Topical corticosteroids are of use in the primary treatment of nasal polyps when they are of a small or medium size (grades 1 and 2) and in the maintenance of any therapeutic improvement.
The efficacy of topical corticosteroids such as betamethasone sodium phosphate nose drops, beclomethasone dipropionate, fluticasone propionate and budesonide nasal sprays in reducing polyp size and rhinitis symptoms has been demonstrated in several randomised, placebo-controlled trials. Beclomethasone dipropionate, flunisolide and budesonide sprays have also been shown to delay the recurrence of polyps after surgery. Placebo-controlled studies of agents that have shown a significant clinical effect in the management of nasal polyposis are reviewed.
- 1.Baumgarten C, Kunkek G, Rudolph R, et at. Histopathologic examinations of nasal polyps of different aetiology. Arch Otolaryngol 1980; 226: 187–97Google Scholar
- 2.Settipane GA. Epidemiology. In: Settipane GA, Lund VJ, Bernstein JM, et al., editors. Nasal polyps: epidemiology, pathogenesis and treatment. Providence (RI): OceanSide Publications, Inc., 1997: 17–24Google Scholar
- 4.Mygind N, Lildholdt T. Medical management. In: Settipane GA, Lund VJ, Bernstein JM, et al., editors. Nasal polyps: epidemiology, pathogenesis and treatment. Providence (RI): OceanSide Publications, Inc., 1997: 147–55Google Scholar
- 5.Kanai N, Denburg J, Jordana M, et al. Nasal polyp inflammation. Effect of topical nasal steroid. Am J Respir Crit Care Med 1994; 150: 1094–100Google Scholar
- 10.Lund VJ, Kennedy DW. Quantification for staging sinusitis. Ann Otol Rhinol Laryngol 1995; 104 Suppl. 167: 17–21Google Scholar
- 11.Mackay IS, Lund VJ. Imaging and staging. In: Mygind N, Lildholdt T, editors. Nasal polyps: an inflammatory disease and its treatment. Copenhagen: Munksgaard, 1997: 137–44Google Scholar
- 12.Sorensen H, Mygind N, Tygstrup I, et al. Histology of nasal polyps of different aetiology. Rhinology 1997; 15: 121–8Google Scholar
- 22.Holopainen E, Grahne B, Malmberg H, et al. Budesonide in the treatment of nasal polyposis. Eur J Respir Dis 1982; 63 Suppl. 122: 221–8Google Scholar
- 23.Lildholdt T, Rundcrantz H, Bende M, et al. Glucocorticoid treatment for nasal polyps. A study of budesonide powder and depot steroid injection. Allergy 1995; 50: 204–9Google Scholar
- 26.Dingsor G, Kramer J, Olsholt R, et al. Flunisolide nasal spray 0.025% in the prophylactic treatment of nasal polyposis after polypectomy. A randomized double blind parallel, placebo controlled study. Rhinology 1985; 23: 49–58Google Scholar